We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Here's an opportunity to get all the details in a new report available from FDAnews.
A 505(b)(2) can provide relatively fast-track approval for a wide range of products, especially for those that represent a limited change from an existing or approved drug. Ideal candidates include:
New chemical entities (NCEs)/new molecular entities (NMEs)
Changes to previously approved drugs
Changes in dosage form, strength or route of administration
Changes from prescription (Rx) indications to over-the-counter (OTC) indications
Substitution of an active ingredient in a combination product
Of course, the devil is in the details — and that's why this report with valuable tips from Kurt Karst, Director with Hyman, Phelps & McNamara,and a widely respected legal authority and blogger on 505(b)(2) issues — is a must have. Readers will learn:
How the 505(b)(2) is similar to and differs from the 505(b)(1) standard NDA and the 505(j) ANDA
How drugs approved under the 505(b)(2) process can obtain either three or five years of patent exclusivity
When applications involving changes to approved drugs can use the 505(b)(2) pathway
How to choose a listed drug for a 505(b)(2) application
About FDA interpretations of the law affecting 505(b)(2) applications
About fees and restrictions involved in using the 505(b)(2) process
Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the FDAnews Online Library — a personalized collection of FDAnews publications that is fully searchable. Contact Customer Service for a quote or more information.
Our Guarantee
Not satisfied with your publication? For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase and we will refund 100 percent of your purchase price.
